Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Viktoria Sattar

Neurology Southlake, TX Nurse Practitioner

NPI 1043681711 CMS profile 10768511

109 River Oaks Dr Ste 150, Southlake, TX 76092

Open in the dashboard

General payments

$9,261

461 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Viktoria Sattar of Southlake, TX is reported in the CMS Open Payments database as having received $9,261 across 461 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,578 117
2024 General $2,246 108
2023 General $1,626 95
2022 General $1,613 75
2021 General $1,198 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Viktoria Sattar
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Viktoria Sattar were reported at $2,578. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Viktoria Sattar Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $1,198 $438 $104–$2,547 $132
2022 $1,613 $442 $103–$2,388 $149
2023 $1,626 $464 $119–$2,312 $160
2024 $2,246 $468 $119–$2,323 $164
2025 $2,578 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,487 94 payments
  2. Amgen Inc. $760 38 payments
  3. Lundbeck LLC $595 33 payments
  4. Teva Pharmaceuticals USA, Inc. $582 30 payments
  5. Genentech USA, Inc. $388 16 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $372 14 payments
  7. EMD Serono, Inc. $359 10 payments
  8. Harmony Biosciences LLC $274 11 payments
  9. Pfizer Inc. $244 20 payments
  10. UCB, Inc. $243 12 payments
  11. Other $3,957 183 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,206 460 payments
  2. Education $55 1 payment
Products named General payments · program years 2021–2025
  1. QULIPTA $701 53 payments
  2. AIMOVIG $663 33 payments
  3. UBRELVY $589 45 payments
  4. VYEPTI $512 28 payments
  5. NURTEC ODT $449 19 payments
  6. AJOVY $445 23 payments
  7. BOTOX $386 22 payments
  8. Ocrevus Zunovo $247 9 payments
  9. VALTOCO $237 8 payments
  10. ZEPOSIA $227 11 payments
  11. Other $5,382 262 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

461 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record